Psychedelics Investing Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
Psychedelics Investing NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
Psychedelics Investing Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
life science investing Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
Psychedelics Investing Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto
Psychedelics Investing Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering
Psychedelics Investing Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression
Psychedelics Investing Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
Alvopetro Announces Q3 2025 Financial Results and an Operational Update Including Record October Sales
Altech Batteries Ltd Service Data Confirms Exceptionally Low Failure Rate for Sodium-Nickel-Chloride Batteries
Allied Critical Metals Expands Santa Helena Breccia with 6.0 Metres of 1.02% WO3 Intercept at Borralha
